Literature DB >> 9367155

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

D M Anderson1, E Maraskovsky, W L Billingsley, W C Dougall, M E Tometsko, E R Roux, M C Teepe, R F DuBose, D Cosman, L Galibert.   

Abstract

Dendritic cells are rare haematopoietic cells that reside in a number of organs and tissues. By capturing, processing and presenting antigens to T cells, dendritic cells are essential for immune surveillance and the regulation of specific immunity. Several members of the tumour necrosis factor receptor (TNFR) superfamily are integral to the regulation of the immune response. These structurally related proteins modulate cellular functions ranging from proliferation and differentiation to inflammation and cell survival or deaths. The functional activity of dendritic cells is greatly increased by signalling through the TNFR family member CD40. Here we report the characterization of RANK (for receptor activator of NF-kappaB), a new member of the TNFR family derived from dendritic cells, and the isolation of a RANK ligand (RANKL) by direct expression screening. RANKL augments the ability of dendritic cells to stimulate naive T-cell proliferation in a mixed lymphocyte reaction, and increases the survival of RANK+ T cells generated with interleukin-4 and transforming growth factor (TGF)-beta. Thus RANK and RANKL seem to be important regulators of interactions between T cells and dendritic cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367155     DOI: 10.1038/36593

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  526 in total

1.  The gene for cherubism maps to chromosome 4p16.

Authors:  V Tiziani; E Reichenberger; C L Buzzo; S Niazi; N Fukai; M Stiller; H Peters; F M Salzano; C M Raposo do Amaral; B R Olsen
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

Review 2.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 3.  Dominant regulation: a common mechanism of monoclonal antibody induced tolerance?

Authors:  K Honey; S P Cobbold; H Waldmann
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

4.  RANK is essential for osteoclast and lymph node development.

Authors:  W C Dougall; M Glaccum; K Charrier; K Rohrbach; K Brasel; T De Smedt; E Daro; J Smith; M E Tometsko; C R Maliszewski; A Armstrong; V Shen; S Bain; D Cosman; D Anderson; P J Morrissey; J J Peschon; J Schuh
Journal:  Genes Dev       Date:  1999-09-15       Impact factor: 11.361

5.  Quantitative trait loci on chromosomes 1, 2, 3, 4, 8, 9, 11, 12, and 18 control variation in levels of T and B lymphocyte subpopulations.

Authors:  M A Hall; P J Norman; B Thiel; H Tiwari; A Peiffer; R W Vaughan; S Prescott; M Leppert; N J Schork; J S Lanchbury
Journal:  Am J Hum Genet       Date:  2002-04-09       Impact factor: 11.025

Review 6.  Osteoprotegerin.

Authors:  U Feige
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

7.  Interactions between immune and bone cells: new insights with many remaining questions.

Authors:  J Lorenzo
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

8.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Authors:  D L Lacey; H L Tan; J Lu; S Kaufman; G Van; W Qiu; A Rattan; S Scully; F Fletcher; T Juan; M Kelley; T L Burgess; W J Boyle; A J Polverino
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

9.  RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Authors:  Christopher A Nelson; Julia T Warren; Michael W-H Wang; Steven L Teitelbaum; Daved H Fremont
Journal:  Structure       Date:  2012-10-02       Impact factor: 5.006

Review 10.  Recent advances in osteoclast biology.

Authors:  Takehito Ono; Tomoki Nakashima
Journal:  Histochem Cell Biol       Date:  2018-02-01       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.